Cancer cell line microarray as a novel screening method for identification of radioresistance biomarkers in head and neck squamous cell carcinoma.
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor
Cell Line, Tumor
Female
Gene Expression Profiling
/ methods
Gene Silencing
Humans
Immunohistochemistry
Male
Microarray Analysis
Middle Aged
RNA Interference
RNA, Small Interfering
/ genetics
Radiation Tolerance
/ genetics
Squamous Cell Carcinoma of Head and Neck
/ etiology
Head and neck cancer
Oct4
Radioresistance
Radiosensitivity
Stemness
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
29 Jul 2021
29 Jul 2021
Historique:
received:
17
12
2020
accepted:
15
07
2021
entrez:
29
7
2021
pubmed:
30
7
2021
medline:
21
10
2021
Statut:
epublish
Résumé
Currently, no clinically useful biomarkers for radioresistance are available in head and neck squamous cell carcinoma (HNSCC). This study assesses the usefulness of Cell Line Microarray (CMA) method to enhance immunohistochemical screening of potential immunohistochemical biomarkers for radioresistance in HNSCC cell lines. Twenty-nine HNSCC cell lines were cultured, cell pellets formalin-fixed, paraffin-embedded, and arrayed. Radioresistance features of the cell lines were combined to immunohistochemical stains for p53, NDFIP1, EGFR, stem cell marker Oct4, and PP2A inhibitor CIP2A. Expression of p53, EGFR or CIP2A did not indicate intrinsic radioresistance in vitro. Stem cell marker Oct4 nuclear positivity and NDFIP1 nuclear positivity was correlated with increased intrinsic radioresistance. The usefulness of CMA in analysis of HNSCC cell lines and discovery of biomarkers is demonstrated. CMA is very well adapted to both testing of antibodies in a large panel of cell lines as well as correlating staining results with other cell line characteristics. In addition, CMA-based antibody screening proved an efficient and relatively simple method to identify potential radioresistance biomarkers in HNSCC.
Sections du résumé
BACKGROUND
BACKGROUND
Currently, no clinically useful biomarkers for radioresistance are available in head and neck squamous cell carcinoma (HNSCC). This study assesses the usefulness of Cell Line Microarray (CMA) method to enhance immunohistochemical screening of potential immunohistochemical biomarkers for radioresistance in HNSCC cell lines.
METHODS
METHODS
Twenty-nine HNSCC cell lines were cultured, cell pellets formalin-fixed, paraffin-embedded, and arrayed. Radioresistance features of the cell lines were combined to immunohistochemical stains for p53, NDFIP1, EGFR, stem cell marker Oct4, and PP2A inhibitor CIP2A.
RESULTS
RESULTS
Expression of p53, EGFR or CIP2A did not indicate intrinsic radioresistance in vitro. Stem cell marker Oct4 nuclear positivity and NDFIP1 nuclear positivity was correlated with increased intrinsic radioresistance.
CONCLUSION
CONCLUSIONS
The usefulness of CMA in analysis of HNSCC cell lines and discovery of biomarkers is demonstrated. CMA is very well adapted to both testing of antibodies in a large panel of cell lines as well as correlating staining results with other cell line characteristics. In addition, CMA-based antibody screening proved an efficient and relatively simple method to identify potential radioresistance biomarkers in HNSCC.
Identifiants
pubmed: 34320941
doi: 10.1186/s12885-021-08618-6
pii: 10.1186/s12885-021-08618-6
pmc: PMC8320194
doi:
Substances chimiques
Biomarkers, Tumor
0
RNA, Small Interfering
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
868Informations de copyright
© 2021. The Author(s).
Références
Cancer Med. 2018 Mar;7(3):698-706
pubmed: 29441695
Oncogene. 2015 Apr 30;34(18):2317-24
pubmed: 24954502
N Engl J Med. 2020 Jan 2;382(1):60-72
pubmed: 31893516
Cancer Res. 2002 Dec 15;62(24):7350-6
pubmed: 12499279
Oncotarget. 2015 Jan 1;6(1):144-58
pubmed: 25474139
Head Neck. 2019 Sep;41(9):3114-3124
pubmed: 31090975
Head Neck. 2014 Jul;36(7):1069-75
pubmed: 25072057
J Oral Pathol Med. 2011 Sep;40(8):621-8
pubmed: 21342274
Cell Prolif. 1996 May;29(5):219-30
pubmed: 8782485
Genes Chromosomes Cancer. 2014 Dec;53(12):972-90
pubmed: 25183546
Genes Chromosomes Cancer. 2016 Jan;55(1):69-81
pubmed: 26395031
Arch Otolaryngol Head Neck Surg. 1988 Apr;114(4):427-31
pubmed: 3348898
Cancer. 1991 Jun 1;67(11):2741-7
pubmed: 2025837
Cancer Med. 2017 Feb;6(2):439-451
pubmed: 28083995
Dis Markers. 2017;2017:8245345
pubmed: 28325958
Nat Med. 1998 Jul;4(7):844-7
pubmed: 9662379
Hum Mol Genet. 2001 Apr;10(7):657-62
pubmed: 11257096
J Oral Pathol Med. 2016 May;45(5):329-37
pubmed: 26436875
Clin Transl Radiat Oncol. 2019 May 22;17:47-50
pubmed: 31206086
J Histochem Cytochem. 2014 Jul;62(7):499-509
pubmed: 24710660
Cancer Treat Rev. 2020 Aug;88:102054
pubmed: 32593915
Methods Mol Biol. 2011;784:139-53
pubmed: 21898218
Oral Oncol. 2018 Dec;87:144-151
pubmed: 30527230
Cancer Biol Ther. 2014;15(12):1593-9
pubmed: 25535895
Biomed Res Int. 2018 Jul 12;2018:3424956
pubmed: 30112378
Science. 2017 Aug 18;357(6352):
pubmed: 28818916
Head Neck. 2015 May;37(5):763-70
pubmed: 24995469
Oncol Rep. 2005 Dec;14(6):1511-7
pubmed: 16273247
Asian Pac J Cancer Prev. 2020 Sep 01;21(9):2539-2547
pubmed: 32986350
Mol Cancer Ther. 2018 Sep;17(9):2060-2071
pubmed: 29970484
BMC Res Notes. 2018 Jul 3;11(1):433
pubmed: 29970180
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Arch Otolaryngol. 1981 Nov;107(11):703-10
pubmed: 7295166
Head Neck. 1998 Jul;20(4):298-303
pubmed: 9588701
Cancer Res. 2013 Nov 15;73(22):6548-53
pubmed: 24204027
Onco Targets Ther. 2015 Jun 12;8:1443-9
pubmed: 26109868
Microarrays (Basel). 2016 May 26;5(2):
pubmed: 27600077
Pathobiology. 2005;72(5):225-32
pubmed: 16374066